Showing results (391-400 of 454) with videos related to
Sort By:
Pageof 46
Gastroenterology|October 20, 2010
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis BE Jenny Heathcote, Patrick Marcellin, Maria Buti, et al.Transplant International : Official Journal of the European Society for Organ Transplantation|October 9, 2021
Deciphering transplant outcomes of expanded kidney allografts donated after controlled circulatory death in the current transplant era. A call for cautionNuria Montero, Néstor Toapanta, Natàlia Pallarès, et al.Journal of Hepatology|October 11, 2015
Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infectionStefan Zeuzem, Christophe Hézode, Jean-Pierre Bronowicki, et al.The American Journal of Gastroenterology|August 10, 2023
Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone SafetyHenry L Y Chan, Maria Buti, Young-Suk Lim, et al.The Lancet. Infectious Diseases|February 25, 2016
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trialMichael Manns, Didier Samuel, Edward J Gane, et al.Alimentary Pharmacology & Therapeutics|September 27, 2024
Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trialsMaria Buti, Young-Suk Lim, Henry Lik Yuen Chan, et al.Frontiers in Microbiology|April 20, 2026
Unveiling pathogens and contaminants: refining metagenomics for clinical diagnosticsMarta Ibañez-Lligoña, Sergi Colomer-Castell, Carolina Campos, et al.JHEP Reports : Innovation in Hepatology|September 29, 2023
Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis BYoung-Suk Lim, Henry L Y Chan, Sang Hoon Ahn, et al.Alimentary Pharmacology & Therapeutics|September 9, 2025
Prediction of Hepatocellular Carcinoma and Other Liver-Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction-Associated Steatotic Liver DiseaseLesley A Patmore, Ivana Carey, Jordan J Feld, et al.Journal of Hepatology|January 29, 2022
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levelsMilan J Sonneveld, Shao-Ming Chiu, Jun Yong Park, et al.Pageof 46